Seto K - Search Results

1

A rat model of human T lymphocyte virus type I (HTLV-I) infection. 1. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats.

Ishiguro N, Abe M, Seto K, Sakurai H, Ikeda H, Wakisaka A, Togashi T, Tateno M, Yoshiki T. Ishiguro N, et al. Among authors: seto k. J Exp Med. 1992 Oct 1;176(4):981-9. doi: 10.1084/jem.176.4.981. J Exp Med. 1992. PMID: 1402668 Free PMC article.

2

A rat model of HTLV-I infection: development of chronic progressive myeloneuropathy in seropositive WKAH rats and related apoptosis.

Seto K, Abe M, Ohya O, Itakura O, Ishiguro N, Ikeda H, Wakisaka A, Yoshiki T. Seto K, et al. Acta Neuropathol. 1995;89(6):483-90. doi: 10.1007/BF00571502. Acta Neuropathol. 1995. PMID: 7676804

3

[Analysis of HAM rat disease developed in HTLV-I carrier rat as an animal model of HAM/TSP in human].

Seto K. Seto K. Hokkaido Igaku Zasshi. 1994 Jul;69(4):867-75. Hokkaido Igaku Zasshi. 1994. PMID: 7959597 Japanese.

4

Attenuated apoptosis in H. pylori-colonized gastric mucosa of Mongolian gerbils in comparison with mice.

Suzuki H, Miyazawa M, Nagahashi S, Mori M, Seto K, Kai A, Suzuki M, Miura S, Ishii H. Suzuki H, et al. Among authors: seto k. Dig Dis Sci. 2002 Jan;47(1):90-9. doi: 10.1023/a:1013219621422. Dig Dis Sci. 2002. PMID: 11837740

5

Effect of water extracts of Rhizopus delemar on the stimulus coupled responses of neutrophils and their modulation by various protein kinase inhibitors.

Zhang J, Sugahara K, Ushikoshi I, Ushikoshi S, Seto K, Kodama H. Zhang J, et al. Among authors: seto k. Clin Chim Acta. 1999 Apr;282(1-2):89-100. doi: 10.1016/s0009-8981(99)00013-3. Clin Chim Acta. 1999. PMID: 10340437

6

Preparation of Mycoplasma hyopneumoniae antigen for the enzyme-linked immunosorbent assay.

Kazama S, Yagihashi T, Seto K. Kazama S, et al. Among authors: seto k. Can J Vet Res. 1989 Apr;53(2):176-81. Can J Vet Res. 1989. PMID: 2523756 Free PMC article.

7

CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.

Kato H, Seto K, Kobayashi N, Yoshinaga K, Meyer T, Takei M. Kato H, et al. Among authors: seto k. Life Sci. 2011 Oct 24;89(17-18):603-8. doi: 10.1016/j.lfs.2011.07.019. Epub 2011 Aug 3. Life Sci. 2011. PMID: 21839751

8

Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.

Kobayashi N, Seto K, Orikawa Y, Hamano H, Yoshinaga K, Takei M. Kobayashi N, et al. Among authors: seto k. Biol Pharm Bull. 2010;33(2):216-22. doi: 10.1248/bpb.33.216. Biol Pharm Bull. 2010. PMID: 20118543 Free article.

9

Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.

Orikawa Y, Kato H, Seto K, Kobayashi N, Yoshinaga K, Hamano H, Hori Y, Meyer T, Takei M. Orikawa Y, et al. Among authors: seto k. Mol Pain. 2010 Oct 28;6:72. doi: 10.1186/1744-8069-6-72. Mol Pain. 2010. PMID: 20979661 Free PMC article.

10

Pharmacological evaluation of analgesic effects of the cholecystokinin2 receptor antagonist Z-360 in mouse models of formalin- and cancer-induced pain.

Yoshinaga K, Horii T, Hamano H, Eta R, Ozaki T, Orikawa Y, Yoshii K, Kawabata Y, Hori Y, Seto K, Takei M, Kuraishi Y. Yoshinaga K, et al. Among authors: seto k. Biol Pharm Bull. 2010;33(2):244-8. doi: 10.1248/bpb.33.244. Biol Pharm Bull. 2010. PMID: 20118547 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

629 results

Search Page

Filters